VRTX · Healthcare

VERTEX PHARMACEUTICALS INC / MA

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-06

• Regulatory Approval MilestonesImportance 41 · Surprise 60
  The market report identifies FDA approval of Vertex’s CRISPR-enabled therapy Casgevy as a development in recombinant DNA technology. It does not provide the approval date, financial impact, or any related revenue or…

News · 2026-11-05

• Liquidity and Debt PositionImportance 64 · Surprise 42
  Vertex borrowed $4.5 billion to fund part of its recent Crinetics acquisition, leaving it with net debt for the first time in many years. The borrowing increased Vertex’s financing costs and compensation expenses,…
• Crinetics Acquisition FinancingImportance 64 · Surprise 42
  Vertex borrowed $4.5 billion to fund part of its Crinetics acquisition. The borrowing left Vertex with net debt for the first time in many years and increased financing costs. The report says the new debt remains small…

News · 2026-11-04

• Guidance / OutlookImportance 62 · Surprise 60
  Vertex raised its full-year revenue guidance to a top end of $13.25 billion. The report identified Q3 2026 revenue of $3.44 billion, up 12% year over year, as the reported quarterly performance accompanying the…
• Guidance and OutlookImportance 62 · Surprise 60
  Vertex raised its full-year revenue guidance, setting the top end at $13.25 billion. The report does not specify the revised lower end of the guidance range or quantify the increase. No further timeframe for the…
• Revenue Performance and MixImportance 54 · Surprise 40
  Q3 2026 total revenue was $3.44 billion, up 12% year over year; U.S. revenue rose 10% and international revenue rose 16%, with about a 1 percentage-point favorable FX impact and $10 million from Crinetics. Cystic…
• CASGEVY Market AdoptionImportance 26 · Surprise 24
  Vertex reported about 200 CASGEVY infusions completed since launch. The product recorded its fourth consecutive quarter with more than 100 patient initiations, indicating continued treatment uptake.
• JOURNAVX Demand and AccessImportance 26 · Surprise 24
  JOURNAVX prescriptions exceeded 750,000, rising more than 40% sequentially. More than 1.6 million patients in the United States have been treated, indicating continued expansion of use in its launch market.
• ALYFTREK Market AccessImportance 26 · Surprise 24
  More than 18,000 patients globally had been treated with ALYFTREK. Reimbursement had been secured in 31 countries outside the United States, reflecting the therapy’s international market access.

10-Q · 2026-11-03

• Operating Expense TrendsImportance 77 · Surprise 82
  Research and development expense increased 35% to $1,320.6 million in the third quarter and 12% to $3,276.0 million in the first nine months of 2026.,Development expense rose 42% to $1,091.6 million in the third quarter, including $235.3 million of compensation for cash-settled unvested Crinetics equity awards and higher outsourced services and other direct expenses.,Selling, general and administrative expense increased 90% to $844.1 million in the third quarter and 52% to $1,920.0 million in the first nine months, including $203.0 million of Crinetics-related compensation and transaction costs.,The company also cited increased headcount and commercial investment for JOURNAVX and the anticipated povetacicept IgAN launch; nine-month AIPR&D declined 18% to $62.5 million.
• Liquidity and Debt PositionImportance 73 · Surprise 66
  Cash, cash equivalents and marketable securities totaled $9,821.2 million at September 30, 2026, down 20% from $12,320.4 million at December 31, 2025, primarily following the Crinetics acquisition and share repurchases.,Working capital decreased 9% to $6,686.0 million, reflecting $1.0 billion of short-term debt and lower cash and short-term securities, partly offset by acquired inventory.,Vertex borrowed the full $4.5 billion under its 2026 Term Loan in September; repayment is scheduled as $1.0 billion in August 2027, $1.0 billion in September 2028 and $2.5 billion in August 2029.,Operating cash flow was $3,196.6 million in the first nine months of 2026, while investing cash flow used $6,578.3 million and financing cash flow provided $3,331.4 million; Vertex said available funds and operating cash flows are expected to fund operations for at least 12 months.
• CASGEVY Pediatric Market ExpansionImportance 72 · Surprise 100
  CASGEVY generated $99.2 million in third-quarter 2026 product revenue, up 30% from the second quarter and more than 400% year over year. The FDA approved CASGEVY for children aged two and older with sickle cell disease…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex completed its acquisition of Crinetics in September 2026 for $85.00 per share in cash, representing $10.0 billion of equity value and $9.0 billion net of acquired cash, cash equivalents and marketable securities.,Vertex financed the acquisition using cash and marketable securities plus $4.5 billion borrowed under the 2026 Term Loan.,The business combination added $8.1 billion of intangible assets to the balance sheet and brought PALSONIFY into Vertex's commercial portfolio.,Vertex recorded $62.5 million of AIPR&D in the first nine months of 2026, including upfront, contingent milestone or other payments under business development transactions.
• Crinetics Acquisition FinancingImportance 71 · Surprise 60
  In September 2026, Vertex acquired Crinetics for $85.00 per share in cash, a total equity value of $10.0 billion, or $9.0 billion net of acquired cash, cash equivalents and marketable securities. Vertex funded the…
• Market Demand TrendsImportance 60 · Surprise 40
  Vertex reported continued growth in cystic fibrosis (CF) therapies and expanding contributions from CASGEVY, JOURNAVX, and PALSONIFY, with total product revenues up 11% in the first nine months of 2026. CF remains the…
• Geographic Market CommentaryImportance 57 · Surprise 40
  In the first nine months of 2026, U.S. total revenue increased 9%, supported by strong patient demand, new ALYFTREK initiations, higher realized net prices in CF, and contributions from CASGEVY, JOURNAVX, and…
• Revenue Performance and MixImportance 54 · Surprise 40
  Third-quarter 2026 total revenue was $3,440.8 million, up 12% from $3,076.4 million, while nine-month revenue rose 11% to $9,761.6 million from $8,811.3 million.,Nine-month CF product revenue increased 8% to $9,396.1 million; ALYFTREK revenue grew 272% to $1,703.8 million, offsetting a 6% decline in TRIKAFTA/KAFTRIO to $7,288.8 million and a 17% decline in other CF products to $403.5 million.,Nine-month CASGEVY revenue increased 255% to $218.5 million and JOURNAVX revenue increased 316% to $136.9 million, while PALSONIFY contributed $10.1 million following the September 1, 2026 Crinetics acquisition.,U.S. revenue increased 9% to $6,001.4 million in the first nine months, and ex-U.S. revenue increased 13% to $3,760.2 million, with ex-U.S. growth also benefiting from favorable foreign exchange.
• Gross Margin DriversImportance 54 · Surprise 40
  Cost of sales was $526.1 million in the third quarter of 2026, up 27% year over year, and $1,408.1 million for the first nine months, up 19%.,Cost of sales rose to 15.3% of net product revenue in the third quarter and 14.4% for the first nine months, compared with 13.5% in each 2025 period.,The higher cost ratio reflected product mix and Crinetics-related PALSONIFY amortization of $15.3 million and acquired inventory step-up expense of $5.4 million for September, partly offset by lower blended CF royalty rates.,Management said PALSONIFY amortization and acquired inventory step-up expenses will increase in future quarters.
• JOURNAVX Demand and AccessImportance 51 · Surprise 64
  More than 750,000 JOURNAVX prescriptions were filled across hospital and retail settings in the third quarter of 2026, an increase of more than 40% from the second quarter and more than four times the 170,000…
• Povetacicept Regulatory ReviewImportance 47 · Surprise 60
  The FDA placed Vertex’s biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy (IgAN) under priority review, with a target action date of November 30, 2026. If approved,…
• ALYFTREK Royalty ArbitrationImportance 40 · Surprise 42
  On October 10, 2025, Royalty Pharma and the Cystic Fibrosis Foundation initiated confidential arbitration over royalties on ALYFTREK sales. Vertex maintains that the royalty burden is 4%, while the claimants allege it…
• PALSONIFY Market AdoptionImportance 34 · Surprise 42
  PALSONIFY is a once-daily oral treatment approved in the U.S. for adults with acromegaly who had an inadequate response to surgery or cannot undergo surgery; Vertex estimates it is an option for 12,000 U.S. adults.…
• IgAN Launch and DifferentiationImportance 34 · Surprise 42
  Vertex is preparing for a potential launch of povetacicept for IgA nephropathy (IgAN), positioning it as a potentially best-in-class dual inhibitor of BAFF and APRIL cytokines to control B-cell activity. The biologics…
• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Vertex reported that PALSONIFY was approved in the European Union in April 2026 and expects to begin launches in European markets in the second half of 2027. Its regulatory submission in Japan was completed in April…
• Capital Return ProgramImportance 32 · Surprise 24
  Vertex repurchased common stock during the first nine months of 2026, contributing to financing cash outflows alongside the Crinetics acquisition financing.,As of September 30, 2026, $2.5 billion remained available under the share repurchase authorization approved by the Board in May 2025.,The authorization has no expiration date and can be discontinued at any time.,Vertex expects to fund future repurchases with a combination of cash on hand and cash generated from operations.
• Income Tax Rate ChangesImportance 30 · Surprise 40
  Vertex's effective tax rate was 18.8% for the first nine months of 2026, below the U.S. statutory rate.,A research and development tax credit study completed in the third quarter of 2026 and excess tax benefits from stock-based compensation reduced the 2026 effective tax rate.,The comparable first-nine-month 2025 effective tax rate was 16.6%, also below the U.S. statutory rate, due to an R&D tax credit study, stock-based compensation tax benefits and greater foreign tax credit utilization, partly offset by uncertain tax-position changes.
• Guidance / OutlookImportance 23 · Surprise 24
  Vertex expects to complete enrollment in both Phase 3 trials of suzetrigine for diabetic peripheral neuropathy by the end of 2026 and share results in mid-2027. It expects to complete enrollment in the Phase 3…
• FX / Currency ImpactImportance 23 · Surprise 22
  Vertex attributed part of its 16% third-quarter 2026 and 13% first-nine-months 2026 ex-U.S. revenue growth to favorable foreign-exchange impacts. Ex-U.S. revenue was $1,271.7 million in the quarter and $3,760.2 million…
• Supply Chain ConstraintsImportance 10 · Surprise 6
  Vertex relies on a global network of third parties, including some in China, alongside internal capabilities to manufacture and distribute commercial products and clinical-trial candidates. It adapts supply chains for…

News · 2026-11-03

• Revenue Performance and MixImportance 54 · Surprise 40
  Vertex reported third-quarter 2026 revenue of $3.44 billion, up 12% year over year and above the $3.40 billion Zacks consensus estimate. Higher sales of Trikafta/Kaftrio and Alyftrek drove growth in the cystic fibrosis…
• Guidance / OutlookImportance 51 · Surprise 60
  Vertex raised its full-year 2026 revenue guidance to $13.15 billion–$13.25 billion after reporting third-quarter revenue of $3.44 billion. The revised outlook reflects the addition of Crinetics Pharmaceuticals,…
• Acquisition / Partnership / DivestitureImportance 40 · Surprise 42
  Vertex acquired Crinetics Pharmaceuticals in September 2026, adding Palsonify to its commercial portfolio. The acquisition expanded Vertex’s presence into rare endocrine diseases and was cited as a contributor to the…
• Regulatory Approval MilestonesImportance 40 · Surprise 42
  Vertex leaders expressed high confidence in the upcoming FDA decision on povetacicept, its investigational treatment for IgA nephropathy. The drug’s PDUFA date is upcoming, though the digest does not specify the date.…
• Povetacicept Launch ProspectsImportance 34 · Surprise 42
  Third-party coverage described povetacicept as Vertex’s prospective first kidney-disease treatment for IgA nephropathy and a potential driver of a renal franchise. Company leaders expressed confidence in the drug’s…
• Net Income and ProfitabilityImportance 31 · Surprise 14
  Vertex reported third-quarter 2026 net income of $653.6 million, or $2.56 per share. Adjusted earnings were $4.76 per share, down 0.8% from $4.80 a year earlier and below the $4.92 Zacks consensus estimate. Higher…
• Operating Expense TrendsImportance 20 · Surprise 24
  Vertex’s third-quarter 2026 adjusted earnings declined 0.8% year over year despite 12% revenue growth, with increased operating expenses cited as an offset. A separate earnings report attributed the EPS miss partly to…
• JOURNAVX Demand and AccessImportance 20 · Surprise 24
  A report characterized JOURNAVX pain-drug sales as light, indicating a slower-than-expected early commercial uptake. The report contrasted this with CASGEVY, which it described as having delivered a definitive beat. No…

Earnings call · 2026-11-02

• Operating Expense TrendsImportance 75 · Surprise 64
  Third-quarter non-GAAP R&D expense was $936 million, up $74 million, or 9%, year over year; approximately $30 million of the increase was attributable to Crinetics. Non-GAAP SG&A was $556 million, up $187 million, or…
• Liquidity and Debt PositionImportance 63 · Surprise 42
  Vertex ended the third quarter with approximately $9.8 billion in cash and investments after closing the Crinetics acquisition. It raised $4.5 billion of term loans to fund part of the acquisition, with an interest…
• CASGEVY Market AdoptionImportance 58 · Surprise 64
  CASGEVY had more than 750 patients initiated worldwide since launch and more than 100 patient initiations in each of four consecutive quarters. Infusions in the first nine months of 2026 were twice the number completed…
• Acquisition / Partnership / DivestitureImportance 56 · Surprise 60
  Vertex closed its acquisition of Crinetics at the beginning of September 2026, adding Palsonify revenue and making rare endocrinology its fourth commercial pillar. Crinetics contributed $10 million of September revenue…
• Guidance / OutlookImportance 53 · Surprise 68
  Vertex raised its 2026 revenue guidance from $13.1 billion–$13.2 billion to $13.15 billion–$13.25 billion, reflecting an expected $40 million–$50 million contribution from Crinetics. The outlook continues to include…
• JOURNAVX Demand and AccessImportance 52 · Surprise 56
  JOURNAVX prescriptions exceeded 750,000 in the third quarter, up more than 40% sequentially, and prescriptions were split roughly evenly between hospital and retail channels. More than 1.6 million U.S. patients had…
• Revenue Performance and MixImportance 48 · Surprise 40
  Third-quarter 2026 total revenue grew 12% year over year, with growth of 10% in the U.S. and 16% internationally; foreign exchange contributed approximately 1 percentage point. CF revenue was $3.3 billion, up 8% year…
• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Vertex reported that CASGEVY was approved for patients ages 2–11 in the U.S., UAE, and Bahrain, and ages 5–11 in the U.K. The company initiated global submissions for ALYFTREK approval in children ages 2–5. For…
• VX-017 Type 1 Diabetes OpportunityImportance 33 · Surprise 42
  Vertex prioritized VX-017 as its lead type 1 diabetes cell-therapy program, describing it as an allogeneic, off-the-shelf, glucose-responsive insulin-producing therapy. Unlike zimislecel, VX-017 is designed for people…
• PALSONIFY Market AdoptionImportance 29 · Surprise 42
  Acromegaly affects approximately 20,000 patients in the U.S. and a similar number across the five largest European markets plus Japan; only 40% to 50% of patients achieve durable remission after surgery, leaving many…
• Capital Return ProgramImportance 27 · Surprise 6
  Vertex repurchased approximately $120 million of shares during the third quarter, buying roughly 250,000 shares. Year to date, it repurchased approximately 2 million shares for $921 million. Management said capital…
• ALYFTREK Market AdoptionImportance 26 · Surprise 24
  ALYFTREK growth is being driven by patients switching from Trikafta and by new patients with rare mutations, with more than 18,000 patients benefiting worldwide. Reimbursement was in place in 31 countries outside the…
• FX / Currency ImpactImportance 24 · Surprise 14
  Foreign exchange contributed approximately 1 percentage point to Vertex's third-quarter 2026 year-over-year revenue growth. The full-year 2026 outlook includes an expected foreign-exchange benefit of roughly 150 basis…
• Gross Margin DriversImportance 20 · Surprise 24
  Third-quarter non-GAAP gross margin was 85.6%, while GAAP gross margin was 84.7%. The GAAP result included intangible-asset and inventory step-up amortization arising from purchase accounting for the Crinetics…
• Povetacicept Regulatory ReviewImportance 20 · Surprise 24
  Vertex said the agency has been involved in reviewing povetacicept, and the company is nearing the end of the review. Management said all data have been submitted, including an entire module on CMC and manufacturing,…
• Income Tax Rate ChangesImportance 17 · Surprise 6
  Vertex’s third-quarter 2026 non-GAAP effective tax rate was 18%, approximately 40 basis points higher than in the third quarter of 2025. Management expects the full-year 2026 non-GAAP effective tax rate to be between…
• Product / Drug Pipeline ProgressImportance 17 · Surprise 24
  Management said the AMPLIFIED inaxaplin study’s cohort 1 comprised patients with modest proteinuria, defined as a 0.3 to 0.7 UPCR range. Most participants did not have FSGS, and management said the cohort’s response…
• Povetacicept Launch ReadinessImportance null · Surprise 24
  Vertex said its IgAN field team was fully hired and trained, with more than 90% having deep nephrology experience and many already conducting disease education. The company described a people-based, technology-enabled…
• Next-Generation CF ModulatorsImportance null · Surprise 42
  Vertex reported that VX-828, tested in small cohorts of patients with F/M/F mutations, reduced sweat chloride in the triple-combination regimen versus a Trikafta baseline, while the dual combination did not change…

8-K · 2026-11-02

• FX / Currency ImpactImportance 43 · Surprise 32
  Vertex said its full-year 2026 total revenue guidance includes an approximately 150-basis-point year-over-year benefit from foreign exchange rate changes. This estimate is net of Vertex’s foreign-exchange hedging…
• ALYFTREK Market AccessImportance 26 · Surprise 24
  Vertex secured reimbursement for ALYFTREK in seven additional countries in the third quarter of 2026, bringing the total to 32 countries. The company also initiated global regulatory submissions for ALYFTREK for…
• PALSONIFY Market AdoptionImportance 26 · Surprise 24
  More than 245 million individuals have access to PALSONIFY, representing approximately 80% of U.S. covered lives. About 500 of the estimated 3,200 U.S. specialty endocrinologists who treat most people with acromegaly…
• Capital Return ProgramImportance 18 · Surprise 14
  Vertex used cash during the first nine months of 2026 to repurchase common stock under its share repurchase program. The company reported $9.0 billion of net cash used for the Crinetics acquisition and share…